Seattle Genetics announced updated results from a Phase 2 clinical trial of Adcetris (brentuximab vedotin) in diffuse large B-cell lymphoma (DLBCL) and other B-cell non-Hodgkin’s lymphoma. Adcetris is an antibody-drug conjugate (ADC) that is designed to be stable in the bloodstream but to release  monomethyl auristatin E (MMAE) upon internalization into CD30-expressing tumor cells.

RELATED: Oncology Resource Center

This Phase 2 trial was designed to assess the antitumor activity, duration of response, and safety profile of Adcetris. Interim data were reported from 50 patients with DLBCL and 18 patients with other B-cell lymphomas. Key findings included:

  • Of the 50 patients with DLBCL, 42% achieved an objective response, including 16% complete remissions and 26% partial remissions.
  • At the time of data analysis, the median duration of response for DLBCL was 5.8 months. For DLBCL patients who achieved a complete remission, the median duration of response was 11.5 months.
  • Objective responses were observed across a broad range of CD30 expression, from DLBCL patients with undetectable CD30 by standard immunohistochemistry testing to those with CD30 expression up to 90%.

The Phase 2 clinical trial has been expanded to assess the activity and tolerability of Adcetris in combination with Rituxan (rituximab; Genentech) as well as to evaluate Adcetris alone in patients with undetectable CD30 expression. In addition, a Phase 2 trial was recently initiated to evaluate Adcetris plus R-CHOP in newly diagnosed, high-risk DLBCL patients, regardless of CD30 expression level.

Adcetris is already approved for the treatment of Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates and for the treatment of systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.

For more information call (855) 473-2436 or visit